How many investments has Third Rock Ventures made?

Third Rock Ventures has 84 tracked investments, 23 of which have exited, including 13 dated in the last 24 months.

What stage does Third Rock Ventures invest at?

Third Rock Ventures invests at the Seed, Series A, Series B, Series C stages.

What is Third Rock Ventures's typical check size?

Third Rock Ventures typically writes checks of $100K – $5M.

What sectors does Third Rock Ventures focus on?

Third Rock Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Third Rock Ventures located?

Third Rock Ventures is headquartered in Boston, US.

Does Third Rock Ventures lead rounds?

Third Rock Ventures typically participates in rounds rather than leading them.

Who does Third Rock Ventures co-invest with?

Third Rock Ventures most often shares deals with GV (Google Ventures), Nextech Invest, Foresite Capital, among 16 tracked co-investors.

Third Rock Ventures

Venture capitalActively deploying

Boston · Seed–Series C · 62 people tracked

Also known as THIRD ROCK VENTURES, LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Third Rock Ventures

Each arrow is one introduction. Sign up to fill in the first one.

1,215 people can intro you to Jigar

Ask Christopher O'Donnell to introduce you to Jigar Raythatha

You →Christopher · together at Triana Bio →Jigar

691 people can intro you to Jeffrey

Ask Jamie Chen to introduce you to Jeffrey Tong

You →Jamie · together at Third Rock Ventures →Jeffrey

357 people can intro you to Alexis

Ask Sam Okafor to introduce you to Alexis Borisy

You →Sam · together at IDRx →Alexis

Andrea van Elsas181 people can intro you
David Kaufman87 people can intro you
Abbie Celniker84 people can intro you

Your email: who you already know at Third Rock Ventures, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Third Rock Ventures team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict

Investment thesis

Third Rock Ventures focuses on creating and building transformative healthcare and life sciences companies. It works closely with founders to discover, launch, build, and scale ventures developing breakthrough therapeutics and medical technologies across areas such as oncology, immunology, genetic medicine, gene therapy, precision genome engineering, and mental health. The firm emphasizes founding companies around ambitious scientific ideas that can address serious unmet medical needs and deliver meaningful patient impact, with a track record of advancing assets to FDA approval and successful acquisitions by major pharmaceutical companies.

Invests inBiotech Digital Health Healthtech Medical Devices Boston United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Seed–Series C

Check

$100K – $5M

Boston, Massachusetts, US

Leads rounds

Follows

Instruments

Equity

Founded

2007

Last 12 months

7 investments

AUM

$3.8B

VC funds

Tracked investments

Unicorns

IPOs

Acquisitions

Team · 62 people

from the firm's website & curated & public directories

Alexis Borisy· General Partner· Greater Bostonin

Alexis Borisy is a life sciences entrepreneur and investor who serves as Co-Founder and Chairman of Curie.Bio. He has been a Co-Founder, CEO, Chairman, or Founding Investor of more than 15 biotech companies, including 10 that listed on the NASDAQ and 3 that were acquired. Borisy has previously served on the board of BIO and as chair of the National Venture Capital Association, and currently serves as Chairman of the Boston Museum of Science.

alexis@curie.bio

Sarah Larson· General Partner

Steven Kafka· General Partner

Abbie Celniker· Partner· Massachusettsin

A biotech executive with over 30 years in senior R&D and leadership roles, she joined Third Rock Ventures in 2016, where she focuses on the formation, development, and strategy of portfolio companies. She previously served as CEO of Eleven Biotherapeutics and Taligen Therapeutics, and held senior roles at Novartis, Millennium Pharmaceuticals, and Wyeth.

acelniker@thirdrockventures.com

Andrea van Elsas· Partner· Oakland, Californiain

Andrea van Elsas joined Third Rock Ventures as a venture partner in 2020 and became partner in 2022. He was previously CSO at Aduro Biotech, co-founded BioNovion, held immuno-oncology roles at Organon, and is a co-inventor on the original anti-CTLA-4 patents behind ipilimumab.

avanelsas@thirdrockventures.com

Charles Homcy· Partner· San Francisco, California

A physician with extensive experience building and leading biotech companies, focused on forming companies developing novel therapeutics. He has been a clinical professor at UCSF Medical School and an attending physician at the San Francisco VA Medical Center since 1997, and previously co-founded Portola Pharmaceuticals, serving as its president and CEO.

Craig Muir· Partner· Massachusettsin

Craig Muir led the identification and integration of drug discovery and development technology platforms across Third Rock's portfolio, built platform systems for R&D and informatics, and contributed to scientific diligence. He helped expand the firm's San Francisco presence. He joined in 2007 and holds a B.S. in Physiology and Chemistry from UC Davis.

David Kaufman· Partner· Boston, Massachusettsin

Physician-scientist who joined Third Rock Ventures as a venture partner in 2020 and became partner in 2022. He previously served as Chief Medical Officer and Head of Translational Development at the Gates Medical Research Institute and led Translational Oncology at Merck Research Laboratories.

dkaufman@thirdrockventures.com

Jeffrey Tong· Partner· West Coastin

Jeffrey Tong is a Partner at Third Rock Ventures, where he draws on operational experience building and growing early-stage biotechnology companies to focus on drug discovery and development across the firm's portfolio. Before joining Third Rock in 2016, he was Executive Chairman of Delinia, CEO of Nora Therapeutics, and part of the founding management team at Infinity Pharmaceuticals. Earlier in his career he worked at McKinsey & Co and was a founding researcher at the Harvard Bauer Center for Genomics Research. Across his career he has raised capital from equity markets and pharma partnerships and led companies from preclinical through Phase 3 development, integrating science and business strategy.

jtong@thirdrockventures.com

Jigar Raythatha· Partner· East Coastin

Partner at Third Rock Ventures who joined in 2022, previously president and CEO of Constellation Pharmaceuticals until its 2021 acquisition and chief business officer at Jounce Therapeutics through its IPO. He holds an MBA from Columbia and a biochemistry/economics degree from Rutgers, and serves on boards at Flare Therapeutics, Synnovation, and TRIANA Biomedicines.

Kevin Gillis· Partner· East Coastin 𝕏

Kevin Gillis is Partner and Chief Operating Officer at Third Rock Ventures, which he joined in 2008. With more than 25 years of financial leadership and management experience, he leads the firm's non-investment activities, including internal operations, finance, legal, communications, and administrative functions. He also oversees fundraising and manages the firm's limited partner relationships. He is especially interested in the firm's preventive medicine initiatives and their potential to change how cancer and other serious diseases are treated.

kgillis@thirdrockventures.com

Neil Exter· Partner· East Coast

Neil Exter is a retired partner at Third Rock Ventures, which he joined in 2007, where he concentrated on the formation, development and strategy of new companies. He brings more than 30 years of operating, business development and strategy experience spanning emerging and established biotechnology and technology companies. He trained as an electrical engineer, earning degrees from Cornell and Stanford before completing an MBA at Harvard Business School.

nexter@thirdrockventures.com

Reid Huber· Partner· East Coastin 𝕏

Reid Huber is a Partner at Third Rock Ventures, which he joined in 2018, where he works on the formation, development and strategy of the firm's portfolio companies. He brings more than 25 years of operating experience in biotechnology, including as a member of the founding scientific team at Incyte in 2002, where he later served as Executive Vice President and Chief Scientific Officer. Earlier in his career he held roles of increasing responsibility at Dupont Pharmaceuticals and Bristol-Myers Squibb, and he completed postdoctoral training at the National Institutes of Health. His investing interests center on companies combining disease genetics, data science and translational medicine to create new medicines.

rhuber@thirdrockventures.com

Robert Tepper· Partner· East Coastin

Robert "Bob" Tepper is a physician-scientist and co-founder of Third Rock Ventures, where he has been a partner since 2007. Before venture, he spent more than three decades building and running R&D organizations in biotech, including serving as president of R&D at Millennium Pharmaceuticals, where he helped transform the company from a drug discovery operation into a fully integrated biopharmaceutical company. He also co-founded Cell Genesys/Abgenix. At Third Rock he concentrates on company formation, scientific strategy, and evaluating new company ideas across the firm's portfolio.

btepper@thirdrockventures.com

Christoph Lengauer· Partner· Boston, Massachusetts, United Statesin 𝕏

Christoph Lengauer is the co-founder and Chief Scientific Officer of Curie.Bio, where he supports founders launching therapeutics companies. His work combines drug development expertise, services, and seed capital to help move companies from initial concept through Series A financing.

christoph@curie.bio

Alan Ezekowitz· Venture Partner· Princeton, New Jerseyin

A physician scientist who spent over 20 years at Harvard Medical School, heading the Laboratory of Developmental Immunology and MassGeneral Hospital for Children. He later led a franchise at Merck and co-founded Abide Therapeutics, acquired by Lundbeck in 2019.

Courtney Wallace· Venture Partner· East Coastin

Venture Partner at Third Rock Ventures focused on creating, developing, and setting strategy for new biotechnology companies. Previously Chief Business Officer of Beam Therapeutics and held business development roles at Celgene, and serves as an independent board director for Kezar Life Sciences.

Jeb Keiper· Venture Partner· East Coastin

Jeb Keiper has over two decades in biotech leadership and strategic transactions. He was CEO of Nimbus Therapeutics from 2014 to 2025, where the company raised over $600 million and oversaw the zasocitinib deal with Takeda. He earlier held senior business development roles at GSK Oncology and worked at Pfizer, McKinsey, and TransForm Pharmaceuticals.

Jeffrey Finer· Venture Partner· West Coastin

Jeffrey Finer is a physician-scientist who joined Third Rock Ventures as a Venture Partner in 2016, where he focuses on drug discovery and development opportunities across the firm's portfolio. He brings roughly 30 years of research and clinical experience, including 18 years leading drug discovery programs, preclinical development, and translational medicine efforts, and has moved several first-in-class drugs into the clinic. He has developed technology platforms integrating science, instruments, and informatics, holds several patents, and has published widely in peer-reviewed journals. He earned his M.D. and Ph.D. in Biochemistry from Stanford and B.S. degrees in Chemistry and Biology from MIT.

John Keilty· Venture Partner· East Coastin 𝕏

John Keilty is a venture partner at Third Rock Ventures, where he works with the platform team to develop and refine technology roadmaps across the portfolio, focusing on identifying and integrating drug discovery and development technology platforms. Before joining Third Rock in 2014, he spent nearly 13 years at Infinity Pharmaceuticals, ultimately serving as vice president of information technology and informatics, where he oversaw information systems, software development, computational science, biostatistics, clinical data management and clinical informatics. He holds a biology degree from Clark University and a master's in bioinformatics from Brandeis University. He is based on the East Coast.

Mary Lynne Hedley· Venture Partner· East Coast

A scientist by training who focuses on new company formation and therapeutic discovery and development, keeping patients central to her work. She co-founded and co-led TESARO before its acquisition by GSK and has held executive leadership roles across biotech and pharma, developing medicines primarily for cancer patients. She holds a B.S. from Purdue, a Ph.D. in Immunology from UT Southwestern, and completed post-doctoral fellowships at Harvard; she joined the firm in 2023.

Richard Ransohoff· Venture Partner· East Coastin 𝕏

Richard Ransohoff is a neurologist who serves as a Venture Partner at Third Rock Ventures, where he focuses on neuroinflammation research and development opportunities. He joined the firm in 2018 from Biogen, and before that spent 30 years at the Cleveland Clinic, where he founded and directed the Neuroinflammation Research Center within the Lerner Research Institute. Trained as a neurologist, he cites a formative moment early in his career — a snowbound day when his clinic was still packed with patients — as a lasting motivation for his work in biotech.

Steve Paul· Venture Partner· East Coastin

Steve Paul is a physician-scientist with over 40 years of experience in neuroscience, molecular neuropharmacology, and CNS drug discovery and development. He spent 18 years at the NIH, including as scientific director of the National Institute of Mental Health, followed by 17 years at Eli Lilly and Company where he rose to Executive Vice President for Science and Technology and President of the Lilly Research Laboratories. He co-founded several CNS-focused biotech companies, including Sage Therapeutics, Voyager Therapeutics (where he was president and CEO), and Karuna Pharmaceuticals (where he served as CEO and chairman). He first joined Third Rock Ventures in 2010 and returned in 2018 as a venture partner, and remains a professor of psychiatry and neurology at Washington University in St. Louis School of Medicine.

Ton Schumacher· Venture Partner· East Coast

Ton Schumacher is a Venture Partner at Third Rock Ventures, where he works on forming new companies in immunology and immuno-oncology. He is a senior member at The Netherlands Cancer Institute and a professor of Immunotechnology at Leiden University. Earlier, he founded AIMM Therapeutics and T cell factory (which was acquired by Kite Pharma) and served as CSO of Kite Pharma EU. His research on T cell recognition in human cancer has earned him honors including the Amsterdam Inventor Award, the Queen Wilhelmina Cancer Research Award, the Meyenburg Cancer Research Award, and the William B. Coley Award.

Vyas Ramanan· Venture Partner· East Coastin 𝕏

Vyas Ramanan is a Venture Partner at Third Rock Ventures, which he joined in 2016, where he helps build new biotech companies at the intersection of biological insight and drug discovery technology to advance medicines for serious diseases. Early in his time at the firm he was involved in the launch of Maze Therapeutics and spent subsequent years helping build its team toward first-in-class medicines. He holds undergraduate and graduate degrees in bioengineering and economics from the University of Pennsylvania, and a Ph.D. from the Harvard-MIT Division of Health Sciences and Technology.

vramanan@thirdrockventures.com

Philip Reilly· Venture Partner· Boston, Massachusettsin

Adam Tebbe· VP Platform Operations· East Coastin

Adam Tebbe joined Third Rock Ventures in 2023 as Vice President of Platform Operations, focusing on applying technology and data science across the portfolio. He holds a B.S. in Computer Science & Biology from Saint Francis University and an M.S. from the Genome Science and Technology program at the University of Tennessee.

Alison Connors· Chief Financial Officer· East Coastin

CPA overseeing financial strategy and operations for the funds, management company and early-stage portfolio companies, with over 20 years of financial accounting experience in biotech and life sciences. She joined Third Rock Ventures in 2008 and holds a B.S. in Accounting and Finance from Boston College.

Amanda Chan· Senior Manager, Fund Accounting· East Coastin

Amanda Chan handles fund reporting, analysis, operations, and tax matters at Third Rock. She previously worked as a Fund Controller at Dynamo Software and as a Tax Manager at PwC, and is a licensed CPA.

Angelo Severino· Senior Executive Assistant and Office Manager· West Coastin

Angelo manages Third Rock's San Francisco office, handling operations and administrative support. He has prior experience in the tech and hospitality industries.

aseverino@thirdrockventures.com

Ava Brunelle· Senior Associate, Fund Accounting· East Coastin

Ava Brunelle joined Third Rock Ventures in 2023 as a Senior Associate in Fund Accounting. She holds a B.S. in Accounting and an M.S. in Taxation from Bentley University.

Cary Pfeffer· Partner· Boston, Massachusettsin

Physician who joined Third Rock in 2007 and led partner development efforts, building relationships with biotech and pharma executives and serving as CBO or CEO of portfolio companies at launch, including work on the Agios-Celgene collaboration. Holds a B.A. from Columbia, an M.D. and MBA from the University of Pennsylvania.

cpfeffer@thirdrockventures.com

Chris Robinson· Chief Talent Officer· East Coastin

Chris leads Third Rock's recruiting team, focused on attracting talent to the firm and its portfolio companies. He joined in 2010, holds a B.S. in Physiology from the University of Massachusetts, and is a former United States Marine.

Corey O'Keeffe· Boston, Massachusetts, United Statesin

Danielle Abdelahad· Vice President, Head of People· East Coastin

Danielle Abdelahad leads Third Rock Ventures' People function, joining in 2025 after leading People & Culture at Jnana Therapeutics through its growth and acquisition. She previously held HR and people operations roles at TRV portfolio companies bluebird bio and Abata Therapeutics, as well as at Wellington Management.

David Moller· Venture Partner· East Coastin

A physician-scientist with over two decades of drug discovery and development experience, David previously held senior R&D leadership roles at Merck and Eli Lilly and served as chief scientific officer at several biotech companies. He began his career as a faculty member at Harvard Medical School.

Erin Moore· Executive Assistant· East Coastin

Erin Moore provides administrative support to venture partners at Third Rock and collaborates with the firm's Discovery project teams. She is motivated by the impact of life sciences work on patients.

emoore@thirdrockventures.com

Gabriella Williams· Senior Director, Management Company Controller· East Coastin

Gabby oversees Management Company reporting, analysis, day-to-day operations, and tax matters at Third Rock. She previously served as a Finance Director at Bain Capital and spent several years in tax at EY working with real estate and private equity clients; she is a licensed CPA.

Greg O'Brien· Quincy, Massachusetts, United States

Jason Gehrke· Entrepreneur-in-Residence· West Coastin

Jason Gehrke joined Third Rock Ventures as an Entrepreneur-in-Residence in 2024, focusing on building immunology and genetic medicine companies. He previously held research leadership roles at Beam Therapeutics, including the BEAM-201 program, and holds a PhD in gene editing from Harvard.

Jefte Drijvers· Greater Bostonin

Jesper Gromada· Boston, Massachusetts, United Statesin

Jesper Gromada is a Venture Partner at Third Rock Ventures with experience as a pharmaceutical executive and drug discovery scientist. He has led multidisciplinary teams and directed programs across multiple disease areas, with responsibility for the development of more than 10 drug candidates and marketed drugs. His scientific work includes over 150 publications and 30 patent applications, along with established partnerships across academic and biopharmaceutical institutions.

Julie Yang· Vice President, Project and Portfolio Analytics· East Coastin

Julie Yang, PhD, is VP of Project and Portfolio Analytics at Third Rock Ventures, joining in 2026 after investment roles at TCG Crossover, Leaps by Bayer, and Bain Capital Life Sciences, plus earlier work as a scientist at Dicerna Pharmaceuticals. She holds a PhD in molecular biology from Weill Cornell and an MBA from INSEAD.

Kevin Munnelly· SVP, Platform Technologies· East Coastin

Kevin leads technology R&D at Third Rock, developing platforms and services for wet lab and data sciences across drug discovery and development. Before joining in 2021, he spent a decade building and leading life science technology startups, including as EIR at Biological Engineering Ventures and as President and CEO of Gen9 (acquired by Ginkgo Bioworks), with earlier roles at Life Technologies, Millennium Pharmaceuticals and Applied Biosystems.

Laura Vitale· Senior Executive Assistant· East Coastin

Laura Vitale is a Senior Executive Assistant at Third Rock Ventures who provides administrative support to the human resources and recruiting teams. She holds a B.S. in Communications from Salem State University and has been with the firm since 2010.

lvitale@thirdrockventures.com

Lee Venezia· Senior Executive Assistant· East Coastin

Lee provides administrative support to Third Rock Ventures' operations team, assisting with planning and strategy initiatives. She has spent the past decade working in biotech.

lvenezia@thirdrockventures.com

Lisa Pepdjonovic· Human Resources & Recruiting Associate· East Coastin

Lisa supports Third Rock's recruiting team with executive search and internal recruiting across all levels. She joined in 2021 and holds a B.S. in Marketing Management from the University of Massachusetts, Boston.

lpepdjonovic@thirdrockventures.com

Lisa Purcell· Entrepreneur-in-Residence· Westchester County, New Yorkin

Immunology and infectious disease drug developer who joined Third Rock Ventures as an Entrepreneur-in-Residence in 2024. She previously served as SVP and Head of Research and Translational Medicine at Vir Biotechnology and led development programs at Regeneron, and co-chaired the NIH's ACTIV partnership during COVID-19.

Nasra Mohamed· Human Resources Specialist· East Coastin

Nasra supports Third Rock's HR functions, including benefits administration, employee relations, and policy updates, and assists with HR and recruiting events. She previously worked as an administrator for an intensive care unit and holds a B.S. in Psychology from Suffolk University.

Olie Luchitsky· Receptionist & Senior Administrative Assistant· West Coastin

Olie Luchitsky joined Third Rock Ventures in 2023, providing administrative support to associates, principals, and projects. She previously worked at healthcare technology company 100Plus as one of its earliest employees and brings over a decade of operational experience.

oluchitsky@thirdrockventures.com

Paul Melone· Senior Director, IT· East Coastin

Paul Melone joined Third Rock Ventures in 2023 as Senior Director of IT after 22 years in various roles at Infinity Pharmaceuticals. He holds a B.A. from St. Anselm College and a B.S. in Civil Engineering from Catholic University.

Rebecca Mancusi· Boston, Massachusetts, United Statesin

Richard Chesworth· Boston, Massachusetts, United Statesin

Sara DeAmicis· Boston, Massachusetts, United Statesin

Scott Frechette· Boston, Massachusetts, United Statesin

Stacey Hero· Boston, Massachusetts, United Statesin

Tracy Williams· Senior Executive Assistant· East Coastin

Tracy Williams supports the firm's operations by providing administrative assistance to partners, venture partners, and staff. She joined Third Rock in 2016 and studied at Salem State University.

twilliams@thirdrockventures.com

Walter Kowtoniuk· Venture Partner· East Coastin

Walter Kowtoniuk, a Ph.D. in Chemical Biology from Harvard, focuses on genetics and genomics to inform disease biology and drug discovery. He works at the intersection of science, business, and strategy to launch patient-centric biotech companies.

Zoe Angell· Senior Executive Assistant· East Coastin

Zoe Angell is a Senior Executive Assistant at Third Rock Ventures who joined in 2008 and manages operations and administrative functions for partners and venture partners. She holds a B.F.A. from the Rhode Island School of Design.

zoe@thirdrockventures.com

Hugo Hilton· Senior Associate· San Francisco Bay Areain 𝕏

Hugo Hilton is a co-founder and VP of Strategy & Operations at Stealth Mode Biotech, holding a DVM and PhD. His background spans strategy, financing, drug development, and business development in venture-backed biotechnology companies.

hhilton@thirdrockventures.com

Richard Ebright· Consultant· Boston, Massachusetts, United Statesin

Beryl Cummings· Senior Associate· San Francisco, California𝕏

Founder mafia

The Third Rock Ventures mafia →

25 people who came through Third Rock Ventures went on to found or lead other companies.

Christoph LengauerPartnerFounded Celsius Therapeutics +3 Reid HuberPartnerFounded MOMA Therapeutics +2 Alexis BorisyGeneral PartnerFounded Foundation Medicine +2 Steve PaulVenture PartnerFounded Voyager Therapeutics, Inc. +1 Peter DiLauraEntrepreneur In ResidenceFounded Helicore Biopharma +1 Philip ReillyVenture PartnerFounded Luna Genetics +1 Wendye RobbinsCompany Formation ConsultantFounded Limerick Biopharma +1 Abbie CelnikerPartnerFounded Eleven Biotherapeutics Charles HomcyPartnerFounded Maze Therapeutics Jeffrey FinerVenture PartnerFounded Septerna Jeffrey TongPartnerFounded Nora Therapeutics Richard RansohoffVenture PartnerFounded Abata Therapeutics

+ 13 more →

What they invest in

from 68 of 84 portfolio companies

Biotech ×62Healthtech ×26Medical Devices ×12AI & Machine Learning ×11Deep Tech ×11Digital Health ×3Mental Health ×2SaaS ×2

HQs:United States×61United Kingdom×1Japan×1Norway×1

Who they back

founder profiles across 8 portfolio companies

25%

solo founders

2 of 8 mapped founding teams

Founding team size:solo founder×22 founders×43 founders×14+ founders×1

Investments · 84 tracked

founders shown can be your intro path

By year:2026 · 3 2025 · 7 2024 · 9 2023 · 6 2022 · 2 2021 · 4 2020 · 6 2019 · 6 2018 · 5 2017 · 1 2016 · 4 2015 · 1176 dated

CytomX Therapeuticscytomx.com in 𝕏NASDAQ: CTMXSeries C · Dec 2014 · $20M

CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.

BiotechHealthtechSouth San Francisco, US

Sean McCarthy(Executive Officer, Director)in Sean A. McCarthy(Chief Executive Officer and Chairman)inMarcia P. Belvin(SVP, Chief Scientific Officer)inDawn Benson(SVP, Quality and Product Manufacturing)inWayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)in

Board seat Neil Exter· per SEC Form D

Co-investorsATEL Ventures Canaan Partners Longitude Capital Pfizer Venture Investments Wellington Management OrbiMed

Fulcrum Therapeutics inNASDAQ: FULCJul 2016SEC filinghigh confidence

Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.

BiotechCambridge, US

Robert Gould(Executive Officer, Director)in Alex C. Sapir(President and Chief Executive Officer, Director)in

Board Alan Ezekowitz(Director)inJames Geraghty(Director)James Collins(Director)

Board seat Mark Levin· per SEC Form D · $55M raise · filed Jul 2017

Co-investorsForesite Capital Sanofi Ventures

KALA BIOkalarx.com inNASDAQ: KALAAug 2015 · $7M

A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.

BiotechArlington, US

Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)in Todd Bazemore(Executive Officer)in Mark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in

Board seat Robert Tepper· per SEC Form D

Co-investorsLongitude Capital SR One Capital Management Wellington Management Ysios Capital Atlas Venture Lux Capital +1 more

Pliant Therapeuticspliantrx.com in 𝕏NASDAQ: PLRXJul 2018SEC filinghigh confidence

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases.

BiotechSouth San Francisco, US

Bernard Coulie(Executive Officer, Director)inJohannes Hull(Executive Officer)Eric Lefebvre(Executive Officer)inKeith Cummings(Chief Financial Officer)in Lily Cheung(Chief Human Resources Officer)inMinnie Kuo(Chief Operating Officer)in

Board seat Charles Homcy Neil Exter· per SEC Form D · $62.1M raise · filed Jul 2018

Co-investorsMenlo Ventures Agent Capital

Revolution Medicinesrevmed.com inNASDAQ: RVMDMar 2018SEC filinghigh confidence

Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.

BiotechHealthtechMedical DevicesRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)

Board seat Neil Exter Barbara Weber· per SEC Form D · $100.3M raise · filed Nov 2019

Co-investorsBain Capital Life Sciences Foresite Capital Gen Capital GV (Google Ventures)Illinois Ventures Nextech Invest+1 more

Tango Therapeuticstangotx.comNASDAQ: TNGXAug 2023

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

Alan Huang(Executive Officer)in Adam Crystal(Executive Officer)inDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)

Board Barbara Weber(Executive Officer, Director)in

Board seatAlexis BorisyReid Huber· per SEC Form D

Co-investorsForesite Capital Nextech Invest NSG Ventures

Voyager Therapeutics, Inc.voyagertherapeutics.comNASDAQ: VYGRSeries A · Apr 2015 · $45M

Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases of the central nervous system, including Alzheimer's disease, ALS, and Parkinson's disease.

BiotechHealthtechLexington, US

Todd Carter(Executive Officer)inRobin Swartz(Executive Officer)inAlfred Sandrock(Executive Officer, Director)Peter Pfreundschuh(Executive Officer)inNathan Jorgensen(Chief Financial Officer; Principal Financial Officer and Principal Accounting Officer)Steven Hyman(Director)

Board seat Mark Levin· per SEC Form D

Co-investorsWellington Management ARCH Venture Partners Fidelity Investments

Agios Pharmaceuticalsagios.com in 𝕏NASDAQ: AGIO

Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.

BiotechHealthtechMedical Devices

Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)Craig B. Thompson, M.D.(Founder)Brian Goff(Chief Executive Officer)in

Co-investorsARCH Venture Partners Flagship Ventures Samsara BioCapital

BioAge Labsbioagelabs.com in 𝕏NASDAQ: BIOAFeb 2024

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)in Eric Morgen(Director)inDov Goldstein(Executive Officer)in

Board Patrick Enright(Director)in

Co-investorsAndreessen Horowitz Elad Gil Felicis Ventures Green Sands Equity IA Seed Ventures Longitude Capital +20 more

Larimar TherapeuticsNASDAQ: LRMR

Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a subcutaneously administered protein designed to deliver an essential protein to mitochondria in patients with Friedreich's ataxia, a rare genetic disease characterized by severe protein deficiency.

BiotechBala Cynwyd, US

Michael Celano(Chief Financial Officer)inCarole Ben Maimon, MD(President and CEO)Carole S. Ben-Maimon(President and Chief Executive Officer)Thomas O. Daniel(Director)Thomas Hamilton(Director)Frank E. Thomas(Director)

Maze Therapeuticsmazetx.com in 𝕏NASDAQ: MAZESeries A · Feb 2019 · $190M

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in

Co-investorsAndreessen Horowitz ARCH Venture Partners Foresite Capital Frazier Life Sciences GV (Google Ventures)Hercules Capital, Inc.+9 more

Rapport Therapeuticsrapportrx.com inNASDAQ: RAPPSeries A · Mar 2023 · $100M

Rapport is a biopharmaceutical company developing novel therapeutics.

BiotechHealthtechMedical Devices

Abe Ceesay(President)Cheryl GaultinDr. SevignyAbraham N. Ceesay(President and Chief Executive Officer and Director)

Co-investorsARCH Venture Partners Sofinnova Ventures Capital Group Johnson & Johnson Innovation – JJDC

Relayrelaytx.com in 𝕏NASDAQ: RLAYJan 2024

Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.

AI & Machine LearningBiotechDeep TechCambridge, US

Donald A. Bergstrom(Executive Officer)in Sanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)

Co-investorsCommonweal Ventures EcoR1 Capital Foresite Capital Nat Turner Nextech Invest SoftBank Vision Fund +2 more

Seaport Therapeuticsseaporttx.com in 𝕏NASDAQ: SPTXOct 2024

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

Daphne Zohar(Founder, CEO & Board Member)in Steven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)in Lana Gladstein(Executive Officer)in Antony Loebel(Executive Officer)in

Co-investorsARCH Venture Partners Foresite Capital HAWKTAIL PureTech Health Sofinnova Ventures CPP Investments +3 more

Azalea Therapeuticsazaleatx.com inSeries A · Nov 2025 · $65M✓ verified

Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.

AI & Machine LearningBiotechMedical DevicesSan Francisco, US

Jennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)Connor Tsuchida(Scientific Cofounder)in

Co-investorsRA Capital Sozo Ventures Yosemite

Casma Therapeuticscasmatx.com in 𝕏Series A · Sep 2020 · $50M✓ verified

Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications.

BiotechDeep TechHealthtechBoston, US

Andrea Ballabio(Founder)Beth Levine(Founder)Herbert Virgin(Founder)James Hurley(Founder)in

Co-investorsAstellas Venture Management LLC Eisai Innovation, Inc.Ono Venture Investment, Inc.The Column Group

Flare Therapeuticsflaretx.com inSeries A · May 2021 · $82M✓ verified

Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.

AI & Machine LearningBiotechDeep TechHealthtech

Jim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)Jacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in

Co-investorsNexTech Ventures Pfizer Ventures Nextech Invest Pfizer Venture Investments ShangBay Capital LLC Agent Capital

Merida Biosciencesmeridabio.com inSeed · Jan 2022✓ verified

Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.

BiotechHealthtech

Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)Michael Naill(Senior Vice President, Process and Product Development)in

Co-investorsBain Capital Life Sciences GV (Google Ventures)Biotechnology Value Fund

Strateosstrateos.com in 𝕏Apr 2019✓ verified

Strateos develops remote access laboratory software and automation platforms that enable scientists to design, execute, and analyze experiments through cloud-based robotics and control systems.

AI & Machine LearningBiotechDeep TechRoboticsSaaSMenlo Park, US

Chris Krueger(Executive Officer)inMark Fischer-Colbrie(Executive Officer, Director)inDavid Lynch, PhD(Chief Executive Officer)Marc Siladi(Chief Operating Officer)in

BoardJoshua Wolfe(Director)Armen Vidian(Director)in

Co-investorsDCVC (Data Collective)Lux Capital BlueStone Venture Partners Alumni Ventures Dolby Family Ventures Harmonix Fund +6 more

Syremis Therapeuticssyremis.com inSeries A · Dec 2025 · $165M✓ verified

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.

BiotechHealthtechMental Health

Co-investorsGV (Google Ventures)Bain Capital Life Sciences

Vibe Biovibebio.com in 𝕏✓ verified

Vibe Bio funds and supports overlooked drug development programs by combining AI and capital to identify promising treatments and reduce funding gaps.

AI & Machine LearningBiotechEnterprise Software

Alok Tayi(CEO & Founder)inAlok Tayi, Ph.D.(Co-founder and CEO)

Co-investors6th Man Ventures AlleyCorp Initialized Capital Lerer Hippeau Undeterred Capital 645 Ventures +1 more

Afferent Pharmaceuticals inJul 2015

BiotechSan Mateo, US

Anthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in

BoardArthur Pappas(Director)Liam Ratcliffe(Director)

Board seatKevin Starr· per SEC Form D

Co-investorsPappas Capital Domain Associates Fidelity Investments Jennison Associates

Arbor Biotechnologiesarbor.bio in 𝕏Oct 2021SEC filingmedium confidence

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.

BiotechDigital HealthMedical DevicesCambridge, US

DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)

Board seatMark Angelino· per SEC Form D · $215M raise · filed Nov 2021

Co-investorsARCH Venture Partners Illumina Ventures Ono Venture Investment, Inc.TCG Crossover Ally Bridge Group Janus Henderson Investors +4 more

Asher Bioasherbio.com in 𝕏Series A · Apr 2024 · $55M

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

Ivana Djuretic(Founder)inAndy Yeung(Founder)inYik Andy Yeung(Executive Officer, Director, Promoter)

Board seatJeffrey TongReid Huber· per SEC Form D

Co-investorsEmles Venture Partners GoAhead Ventures Mission Bay Capital Mission Biocapital RA Capital Wellington Management +8 more

Constellation Pharmaconstellationpharma.com in 𝕏Series A · Dec 2015 · $32Macquired by Novartis

Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.

BiotechHealthtechCambridge, US

Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)

Board seat Robert Tepper· per SEC Form D

Co-investorsAvoro Capital Advisors Bain Capital Life Sciences The Column Group Venrock

Corvia Medicalcorviamedical.com in 𝕏Series C · Jun 2025 · $11M

Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.

BiotechTewksbury, US

George J. Fazio(Executive Officer, Director)inDan B. Curtis(Executive Officer)

Board Paul LaViolette(Director)in Gerald Brunk(Director)in Irit Yaniv(Director)in

Board seatKevin Gillis Mark Levin· per SEC Form D

Co-investorsAccelmed Partners Lumira Ventures General Catalyst SV Health Investors

Element Scienceelementscience.com inAug 2016

Element Science is a medical technology company that develops the Jewel, an FDA-approved adhesive-based wearable cardioverter defibrillator designed to protect patients at risk of sudden cardiac arrest.

AI & Machine LearningDigital HealthHardwareHealthtechMedical DevicesSan Francisco, US

Uday N. Kumar(Executive Officer, Director)in Uday Kumar(Founder)in

BoardRussell Hirsch(Director)Krishna Yeshwant(Director)inWilliam H. Kucheman(Director)

Board seat Neil Exter· per SEC Form D

Co-investorsGV (Google Ventures)Deerfield Management Company

Faze Medicines inSeries A · Dec 2020 · $81M

BiotechCambridge, US

Ed Freedman(Executive Officer, Director)

Board Cary Pfeffer(Executive Officer, Director)in

Partner Cary Pfeffer· quoted

Board seat Charles Homcy Robert Tepper· per SEC Form D

Co-investorsNovartis Venture Fund

Global Blood Therapeutics inDec 2014acquired by Pfizer · Aug 2022 · $5.4B

Global Blood Therapeutics was a South San Francisco biopharmaceutical company founded in 2011 focused on treatments for sickle cell disease.

South San Francisco, US

John Schembri(Executive Officer)inTed W. Love(Executive Officer, Director)in

BoardCharles Homcy, M.D.(Director)

Board seatKevin Starr· per SEC Form D

Co-investorsRA Capital Ridgeback Capital

Imaginabimaginab.com in 𝕏Mar 2016SEC filingmedium confidence

Imaginab develops advanced imaging solutions for immuno-oncology that visualize immune cell activity and treatment response without invasive biopsies.

BiotechHealthtechMedical DevicesInglewood, US

Anna M. Wu(Executive Officer, Director)Jeffrey D. Quan(Executive Officer)Benjamin Chen(Executive Officer)inJennifer Keppler(President and Chief Operating Officer)Christian Behrenbruch(Chief Executive Officer)

BoardIsaac Bright(Director)

Board seat Abbie Celniker· per SEC Form D · $9.5M raise · filed Apr 2016

Co-investorsCycad Group LLC Raptor Group

Jounce Therapeuticsjouncetx.comSeries A · Apr 2015 · $47MAcquired

Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.

BiotechCambridge, US

Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)inRichard Murray(Executive Officer, Director)

Board seatRobert Kamen Cary Pfeffer Robert Tepper· per SEC Form D

Co-investorsBoutique Venture Partners GENERAL INCEPTION Nextech Invest Sofinnova Ventures Venture Capital Investment Management

Kamal Therapeuticskamaltherapeutics.comNov 2025SEC filingmedium confidence

Kamal Therapeutics is developing an intravenous recombinant human decorin as a treatment for dystrophic epidermolysis bullosa.

BiotechHealthtechHingham, US

Mark de Souza(Executive Officer, Director)Alexander Silver(Director)Hal Landy(Director)Joff Masukawa(Director)Deborah Ramsdell(Executive Officer, Director)

Board seat Philip Reilly· per SEC Form D · $17.3M raise · filed Nov 2025

Manifoldmanifold.bio inNov 2024SEC filingmedium confidence

Manifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs.

AI & Machine LearningBiotechDeep TechBoston, US

Gleb Kuznetsov(Co-Founder & CEO)in Pierce Ogden(Co-Founder & CTO)in

BoardJory Bell(Director)Jeff Huber(Director)Steven Holtzman(Director)

Board seatSteven J. Kafka· per SEC Form D · $32.8M raise · filed Dec 2024

Co-investorsPlayground Global Fifty Years FPV Horizons Ventures Triatomic Capital

Neon Therapeuticsneontherapeutics.comDec 2016

BiotechCambridge, US

Richard Gaynor, M.D.(Executive Officer)inRobert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)inEric Lander(Director)Hugh Dowd(Executive Officer, Director)

BoardCary Pfeffer, M.D.(Director)

Board seatRobert Kamen Robert Tepper· per SEC Form D

Co-investorsNextech Invest Sofinnova Ventures Clal Biotechnology Industries

NinePoint Medical inSeries A · Nov 2015 · $33M

HealthtechBedford, US

Christopher von Jako(Executive Officer, Director)inJudith M. Huber(Executive Officer)inCharles Carignan(Executive Officer, Director)Eric Swanson(Director)

Board Russell Hirsch(Director)

Board seat Mark Levin· per SEC Form D

Co-investorsProspect Venture Partners

PanOpticapanopticapharma.comApr 2014 · $30M

BiotechMt. Arlington, US

Paul Chaney(Executive Officer, Director)

BoardDavid Guyer(Director)Bruce Peacock(Director)Kevin Starr(Director)inLutz Giebel(Director)

Board seat Abbie Celniker· per SEC Form D

Co-investorsAstellas Venture Management LLC Agent Capital SV Health Investors SV Life Sciences

Platelet BioGenesisplateletbiogenesis.com inJun 2019SEC filingmedium confidence

BiotechChestnut Hill, US

Joseph Italiano(Director)inJonathan Thon(Director)Sven Erik Karlsson(Executive Officer)Peter Finn(Executive Officer)

Board seat Philip Reilly· per SEC Form D · $26.4M raise · filed Aug 2019

Co-investorsBoston Harbor Angels Qiming Healthcare Vivo Capital

Rheos Medicines inMar 2018

BiotechCambridge, US

Gad Soffer(Executive Officer)Ryan Cohlhepp(Executive Officer)J. Duncan Higgons(Director)Jeffrey Bluestone(Director)Dan Matloff(Executive Officer)Sanjay Keswani(Executive Officer, Director)

Board seat Abbie Celniker Cary Pfeffer· per SEC Form D

Rhythm Pharmaceuticalsrhythmtx.com in 𝕏Aug 2015SEC filingmedium confidence

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Keith Gottesdiener(Executive Officer, Director)in Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in

Board Edward T. Mathers(Director)in Jonathan Silverstein(Director)in

Board seat Neil Exter· per SEC Form D · $40M raise · filed Dec 2015

Co-investorsForesite Capital HEALTHCARE ROYALTY PARTNERS New Enterprise Associates (NEA)Pfizer Venture Investments Wellington Management OrbiMed

Septernasepterna.comSeries A · Jun 2023 · $100M

Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.

AI & Machine LearningBiotechDeep TechSouth San Francisco, US

Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in

Board seat Jeffrey Tong· per SEC Form D

Co-investorsCatalio Capital Management, LP RA Capital Samsara BioCapital Vertex Ventures HC

Strand Therapeutics inMay 2025SEC filingmedium confidence

Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.

BiotechBoston, US

Tasuku Kitada(Executive Officer, Director, Promoter)in Jacob Becraft(Executive Officer, Director, Promoter)inSamta Kundu(Executive Officer)in

Board Ala Alenazi(Director)in Pegah Ebrahimi(Director)in

Board seat Jeb Keiper· per SEC Form D · $120.1M raise · filed Mar 2026

Co-investorsJIC Venture Growth Investments Kinnevik Playground Global Amgen Ventures ANRI FPV +2 more

Synnovation Therapeuticssynnovationtx.com inSeries A · Dec 2023 · $100M

A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.

BiotechDeep TechMedical DevicesWilmington, US

Liangxing Wu(Executive Officer, Director)inWenqing Yao(Executive Officer, Director)inTing Feng(Director)

Board seat Reid Huber· per SEC Form D

Co-investorsNextech Invest The Innovation Space

Terremotobioterremotobio.comSeries A · Apr 2026 · $108M

Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.

BiotechDeep TechSouth San Francisco, US

Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)in

BoardMichael Goller(Director)Peter Thompson(Director)in

Board seatReid Huber· per SEC Form D

Co-investorsEcoR1 Capital OrbiMed RA Capital Novo Holdings Osage University Partners

Triana Biotrianabio.com in 𝕏Dec 2025SEC filingmedium confidence

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

Patrick Trojer(President & Chief Executive Officer)in

Board seatJigar Raythatha· per SEC Form D · $120.1M raise · filed Dec 2025

Co-investorsAscenta Capital Atlas Venture Lightspeed Venture Partners RA Capital Bessemer Venture Partners Pfizer Ventures +3 more

Ablexisablexis.comSeries A · Jun 2010 · $12M

Ablexis develops the AlivaMab Mouse, a transgenic mouse platform for antibody drug discovery used by major pharmaceutical companies.

BiotechDeep Tech

Larry(CEO and Founder)

Co-investorsCalifornia Technology Ventures Pfizer Venture Investments

Alcrestaalcresta.com inSeries A · Apr 2012 · $10M

Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases.

BiotechHealthtechMedical DevicesMassachusetts, US

Daniel Orlando(Chief Executive Officer)inTasos Konidaris(Executive Officer)inMartin Paz(Executive Officer)inRobert Gallotto(Executive Officer)in Daniel Tasse(Executive Officer, Director)inWilliam Scheinler(Executive Officer)in

Co-investorsHealthQuest Capital Bessemer Venture Partners Frazier Life Sciences

ARTBIOartbio.com in 𝕏Series A · Jul 2025 · $90M

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.

BiotechHealthtechMedical DevicesOslo, NO

Roy Larsen(Scientific Founder)Øyvind Bruland(Scientific Founder)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)Amra Demirovic(Chief Human Resources Officer)Nicole Hadas(Chief Legal Officer)

Co-investorsB Capital Group B4 Capital F-Prime Capital Sofinnova Ventures Alexandria B Capital +2 more

Candid Therapeuticscandidrx.com inAug 2024

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsForesite Capital LifeSci Venture Partners OrbiMed Samsara BioCapital TCG Crossover venBio Partners +1 more

CARGO Therapeuticscargo-tx.com inSeries A · Feb 2023 · $200M

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

BiotechSan Mateo, US

Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)

BoardAbraham Bassan(Director)

Co-investorsNextech Invest Red Tree Venture Samsara BioCapital Wellington Management Ally Bridge Group Janus Henderson Investors +1 more

Celsius Therapeuticscelsiustx.comacquired by AbbVie

Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine.

HealthtechCambridge, US

Tariq Kassum(Executive Officer, Director)in Michael Boretti(Executive Officer)in Christoph Lengauer(Executive Officer, Director)in

Co-investorsCatalio Capital Management, LP Fast Track Initiative GV (Google Ventures)Alexandria Casdin Capital

Clasp Therapeuticsclasptx.com inSeries A · Mar 2024 · $150M

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.

BiotechHealthtechCambridge, US

Co-investorsCatalio Capital Management, LP Cure Ventures Vivo Capital Catalio Capital Management Novo Holdings

Flareflare.runJul 2026 · $85M

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANOBAKA CARTA VENTURES, Inc.Spiral Ventures Agent Capital Casdin Capital Invus +2 more

Flaregetflare.co.uk inJul 2026 · $85M

Flare is a Shopify app that lets merchants set delivery-date rules by postcode, product, and shipping method so customers only see fulfillable dates at checkout, with automation for cut-off times, order tagging, and 3PL syncing.

E-commerceLogistics & Supply ChainRetail TechSaaSLondon, GB

Daniel Parekh-Hill(CEO)inAlex Hooper(CTO)in

Co-investorsEntrepreneur First Agent Capital Base10 Partners Casdin Capital Inovia Capital Invus +3 more

Genetix Biotherapeutics Inc.genetixbiotx.comSeries B · Mar 2010 · $35M

Genetix Biotherapeutics develops gene addition therapies that use a patient's own cells to treat the underlying cause of rare diseases with a single dose, with a focus on hematology conditions such as sickle cell disease.

BiotechDeep TechHealthtech

Insitroinsitro.com in 𝕏Mar 2020 · $143M

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

Daphne Koller(Founder & CEO)in Duane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in

Board Robert Nelsen(Director)Vijay Pande(Director)in

Co-investorsAndreessen Horowitz ARCH Venture Partners Deviation Capital Foresite Capital GV (Google Ventures)HOF Capital +9 more

MOMA Therapeuticsmomatx.com in 𝕏May 2022 · $150M

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in

Co-investorsLifeSci Venture Partners Nextech Invest Alexandria Casdin Capital Creacion Ventures Goldman Sachs +3 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Abata Therapeutics Allena Pharmaceuticals Atterocor Cardurion Pharmaceuticals, Inc.Cedilla Therapeutics, Inc.Decibel TherapeuticsEleven Biotherapeutics Goldfinch BioPharma Hookipa Pharma Lycera Myokardia Sage TherapeuticsAgiosAmbys MedicinesCibiemCytomX Therapeutics HoldingsKaruna TherapeuticsLotus Tissue RepairMagenta Therapeutics ManaT Bio Marea Therapeutics, Inc.Sesen BioSoffio MedicalTaris BioTaris BiomedicalThrive Earlier DetectionTopica PharmaceuticalsTrace Neuroscience

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 23

14 IPOs · 9 acquisitions · showing 22

CytomX TherapeuticsNASDAQ: CTMXFulcrum TherapeuticsNASDAQ: FULCKALA BIONASDAQ: KALAPliant TherapeuticsNASDAQ: PLRXRevolution MedicinesNASDAQ: RVMDTango TherapeuticsNASDAQ: TNGXVoyager Therapeutics, Inc.NASDAQ: VYGRAgios PharmaceuticalsNASDAQ: AGIOBioAge LabsNASDAQ: BIOALarimar TherapeuticsNASDAQ: LRMRMaze TherapeuticsNASDAQ: MAZERapport TherapeuticsNASDAQ: RAPPRelayNASDAQ: RLAYSeaport TherapeuticsNASDAQ: SPTXConstellation Pharmaacq. by NovartisDecibel Therapeuticsacq. by RegeneronGlobal Blood Therapeuticsacq. by PfizerMyokardiaacq. by Bristol Myers SquibbCelsius Therapeuticsacq. by AbbVieTaris Bioacq. by Johnson & JohnsonTaris Biomedicalacq. by Johnson & Johnson (Janssen)Topica Pharmaceuticalsacq. by Medicis

Portfolio news

latest coverage across their companies

Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer

Flare Therapeutics · globenewswire.com · Jun 30, 2026

Terremoto Biosciences Raises $108M in Series C Funding

Terremotobio · finsmes.com · Apr 15, 2026

Casma Therapeutics Receives MJFF Support to Advance Research on TRPML1 in Parkinson’s Disease - Casma Therapeutics

Casma Therapeutics · casmatx.com · Mar 10, 2026

Azalea Therapeutics Raises $82M in Series A Funding

Azalea Therapeutics · finsmes.com · Nov 4, 2025

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure

ARTBIO · prnewswire.com · Jul 29, 2025

Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt | Corvia Medical

Corvia Medical · corviamedical.com · Jun 17, 2025

Merida Biosciences Raises $121M in Series A Funding

Merida Biosciences · finsmes.com · Apr 9, 2025

IPO stake values · per SEC filings · 8

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Relay	15.4%	$20.00	Jul 2020	$267.2M
Larimar Therapeutics	21.4%	$35.00	Jan 2015	$196.1M
Voyager Therapeutics, Inc.	42.5%	$14.00	Nov 2015	$154.9M
Rapport Therapeutics	22.9%	$17.00	Jun 2024	$137.8M
Maze Therapeutics	16.0%	$16.00	Jan 2025	$112.4M
CytomX Therapeutics	24.8%	$12.00	Oct 2015	$104M
Seaport Therapeutics	3.9%	$18.00	May 2026	$37.1M
KALA BIO	7.1%	$15.00	Jul 2017	$24.8M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Public market activity · per SEC filings

what is this? ⓘ

Files 13F institutional holdings reports · latest Nov 2015

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Third Rock Ventures made?: Third Rock Ventures has 84 tracked investments, 23 of which have exited, including 13 dated in the last 24 months.
What stage does Third Rock Ventures invest at?: Third Rock Ventures invests at the Seed, Series A, Series B, Series C stages.
What is Third Rock Ventures's typical check size?: Third Rock Ventures typically writes checks of $100K – $5M.
What sectors does Third Rock Ventures focus on?: Third Rock Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Third Rock Ventures located?: Third Rock Ventures is headquartered in Boston, US.
Does Third Rock Ventures lead rounds?: Third Rock Ventures typically participates in rounds rather than leading them.
Who does Third Rock Ventures co-invest with?: Third Rock Ventures most often shares deals with GV (Google Ventures), Nextech Invest, Foresite Capital, among 16 tracked co-investors.

Media · Podcasts & interviews

from their channel

Connected By Our Mission

Third Rock Ventures

Third Rock: First Decade Video

Third Rock Ventures

Images

Co-investors · 36

RA Capital

RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.

Both backed · 10

BioAge Labs KALA BIO Asher Bio Azalea Therapeutics Global Blood Therapeutics Septerna Terremotobio Triana BioTaris BiomedicalTrace Neuroscience

Nextech Invest

Nextech Invest is a Zurich-based investor backing emerging biotechnology companies worldwide, focused on advancing precision medicine and transformative cancer therapies.

Both backed · 10

Relay Tango TherapeuticsRevolution MedicinesCARGO Therapeutics Flare Flare Therapeutics Jounce Therapeutics MOMA Therapeutics Neon Therapeutics Synnovation Therapeutics

$648K – $3.2M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 9

Maze TherapeuticsRevolution MedicinesCelsius Therapeutics Element Science Insitro Magenta Therapeutics Merida Biosciences Syremis TherapeuticsTrace Neuroscience

$250K – $50M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 9

Agios Pharmaceuticals Maze Therapeutics Rapport Therapeutics Seaport Therapeutics Voyager Therapeutics, Inc.Arbor Biotechnologies Insitro Lycera Sage Therapeutics

$50K – $250M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

Both backed · 8

BioAge Labs Rapport Therapeutics Seaport Therapeutics ARTBIO Jounce Therapeutics Marea Therapeutics, Inc.Neon TherapeuticsKaruna Therapeutics

$100K – $15M

Casdin Capital

Casdin Capital is an investment firm focused on the life sciences, investing across healthcare, biotechnology, synthetic biology, and related technology.

Both backed · 7

Maze Therapeutics Cedilla Therapeutics, Inc.Celsius Therapeutics Flare Insitro Magenta Therapeutics MOMA Therapeutics

OrbiMed

OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 5

BioAge Labs CytomX Therapeutics Candid Therapeutics Rhythm Pharmaceuticals Terremotobio

$1M – $75M

Pfizer Venture Investments

Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.

Both backed · 5

CytomX Therapeutics Flare Therapeutics Rhythm Pharmaceuticals Triana BioAblexis

$5M – $20M

SV Health Investors

SV Health Investors is a global private equity and venture capital platform dedicated to healthcare, running specialized funds across biotechnology (including dementia), healthcare growth equity, and medtech.

Both backed · 5

BioAge Labs Corvia Medical PanOpticaCibiemSoffio Medical

$1M – $20M

Samsara BioCapital

Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.

Both backed · 5

Agios Pharmaceuticals Candid Therapeutics CARGO Therapeutics SepternaDecibel Therapeutics

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 4

KALA BIO Magenta Therapeutics Triana BioTrace Neuroscience

$500K – $1M

General Catalyst

General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.

Both backed · 3

Maze Therapeutics Relay Corvia Medical

$30M

▶24 more co-investors

Canaan Partners venBio Partners The Column Group Vivo Capital Catalio Capital Management, LP Bessemer Venture Partners SR One Capital Management Catalio Capital Management Astellas Venture Management LLC B Capital Group F-Prime Capital Venrock S32 Johnson & Johnson Innovation – JJDC Flagship Pioneering Frazier Healthcare Partners Ysios Capital Bain Capital Ventures Unknown Ventures Foundry Flare Capital Partners Forbion Andera Partners Activate Venture Partners

Firms observed investing alongside Third Rock Ventures, from public investor directories. Shared companies are the overlap with Third Rock Ventures's recorded portfolio.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

Vesalius Biocapital III Partners SàRL

Vesalius Biocapital is a European life sciences venture capital investor focused on later-stage companies in drug development, medical devices and diagnostics, and eHealth/mHealth. Its active fund, Vesalius Biocapital III, closed in May 2019 with €120 million in commitments.

$10.8M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Seed Investors & VC Firms in North America Seed Investors & VC Firms in United States Series A Investors & VC Firms in North America Series B Investors & VC Firms Series A Investors & VC Firms in United States Healthtech Investors & VC Firms Healthtech Seed Investors & VC Firms Series C Investors & VC Firms